This publication is intended as an educational resource for specialist physicians. It reviews the clinical features of eosinophilic granulomatosis with polyangiitis (EGPA), and covers the role of eosinophils in disease pathophysiology. Guidance for distinguishing EGPA from other eosinophilic and vasculitic diseases is presented. The publication then provides an overview of the management of EGPA, including recommendations for use of the anti-interleukin (IL)-5 agent mepolizumab from international guidelines. This publication has been commissioned and funded by GSK. The content is based on published studies and the author’s opinions and may not reflect the views of GSK. Please consult the full Data Sheets for any medications mentioned in this article at www.medsafe.govt.nz before prescribing. Treatment decisions based on these data are the full responsibility of the prescribing physician. All trademarks mentioned in this review are the property of their respective owners.
Please login below to download this issue (PDF)